Literature DB >> 30578415

Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map.

Jennifer Huynh1, Ashwini Chand1, Daniel Gough2,3, Matthias Ernst4.   

Abstract

The tightly orchestrated temporal and spatial control of signal transducer and activator of transcription 3 (STAT3) activity in epithelial, immune and stromal cells is critical for wound healing and tissue repair. Excessive STAT3 activation within cancer cells and cells of the tumour microenvironment can be viewed as a neoplastic mimic of an inflammation-driven repair response that collectively promotes tumour progression. In addition to the canonical transcriptional pathways by which STAT3 promotes stem cell-like characteristics, survival, proliferation, metastatic potential and immune evasion, cytoplasmic STAT3 activity fuels tumour growth by metabolic and other non-transcriptional mechanisms. Here, we review the tumour-modulating activities of STAT3 in light of its role as a signalling node integrating inflammatory responses during wound healing. Accordingly, many of the cytokines that contribute to the para-inflammatory state of most solid malignancies converge on and underpin dysregulated STAT3 activity. Targeting of these cytokines, their cognate receptors and associated signalling cascades in clinical trials is beginning to demonstrate therapeutic efficacy, given that interference with STAT3 activity is likely to simultaneously curb the growth of cancer cells and augment antitumour immunity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30578415     DOI: 10.1038/s41568-018-0090-8

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  136 in total

1.  BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.

Authors:  Hanan S Elsarraj; Yan Hong; Darlene Limback; Ruonan Zhao; Jenna Berger; Stephanie C Bishop; Aria Sabbagh; Linzi Oppenheimer; Haleigh E Harper; Anna Tsimelzon; Shixia Huang; Susan G Hilsenbeck; Dean P Edwards; Joseph Fontes; Fang Fan; Rashna Madan; Ben Fangman; Ashley Ellis; Ossama Tawfik; Diane L Persons; Timothy Fields; Andrew K Godwin; Christy R Hagan; Katherine Swenson-Fields; Cristian Coarfa; Jeffrey Thompson; Fariba Behbod
Journal:  NPJ Breast Cancer       Date:  2020-04-24

2.  ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3.

Authors:  Yang-Ling Li; Lin-Wen Wu; Ling-Hui Zeng; Zuo-Yan Zhang; Wei Wang; Chong Zhang; Neng-Ming Lin
Journal:  Oncogene       Date:  2020-08-21       Impact factor: 9.867

3.  Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.

Authors:  Dayson Moreira; Sagus Sampath; Haejung Won; Seok Voon White; Yu-Lin Su; Marice Alcantara; Chongkai Wang; Peter Lee; Ellie Maghami; Erminia Massarelli; Marcin Kortylewski
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

4.  Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice.

Authors:  Ashleigh R Poh; Amy R Dwyer; Moritz F Eissmann; Ashwini L Chand; David Baloyan; Louis Boon; Michael W Murrey; Lachlan Whitehead; Megan O'Brien; Clifford A Lowell; Tracy L Putoczki; Fiona J Pixley; Robert J J O'Donoghue; Matthias Ernst
Journal:  Cancer Immunol Res       Date:  2020-01-28       Impact factor: 11.151

5.  Liposome Delivery of Natural STAT3 Inhibitors for the Treatment of Cancer.

Authors:  Max Kullberg; Alexandra Francian; Ameneh Arabi; Troy Olsson; Kristine Mann; Holly A Martinson
Journal:  Pharm Front       Date:  2019-11-28

6.  Beclin-1 as a neutrophil-specific immune checkpoint.

Authors:  Yu-Lin Su; Marcin Kortylewski
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

7.  Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

Authors:  Hao Wang; Wei Hou; Aldeb Perera; Carlee Bettler; Jordan R Beach; Xianzhong Ding; Jun Li; Mitchell F Denning; Asha Dhanarajan; Scott J Cotler; Cara Joyce; Jun Yin; Fowsiyo Ahmed; Lewis R Roberts; Wei Qiu
Journal:  Cell Rep       Date:  2021-02-23       Impact factor: 9.423

8.  PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.

Authors:  Tianzhi Huang; Yongyong Yang; Xiao Song; Xuechao Wan; Bingli Wu; Namratha Sastry; Craig M Horbinski; Chang Zeng; Deanna Tiek; Anshika Goenka; Fabao Liu; Cameron W Brennan; John A Kessler; Roger Stupp; Ichiro Nakano; Erik P Sulman; Ryo Nishikawa; Charles David James; Wei Zhang; Wei Xu; Bo Hu; Shi-Yuan Cheng
Journal:  Mol Cell       Date:  2021-02-03       Impact factor: 17.970

9.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

10.  IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.

Authors:  Rasmus Siersbæk; Valentina Scabia; Sankari Nagarajan; Igor Chernukhin; Evangelia K Papachristou; Rebecca Broome; Simon J Johnston; Stacey E P Joosten; Andrew R Green; Sanjeev Kumar; Julia Jones; Soleilmane Omarjee; Ruben Alvarez-Fernandez; Silvia Glont; Sarah J Aitken; Kamal Kishore; Danya Cheeseman; Emad A Rakha; Clive D'Santos; Wilbert Zwart; Alasdair Russell; Cathrin Brisken; Jason S Carroll
Journal:  Cancer Cell       Date:  2020-07-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.